导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.02% | 359/1840 |
| 近一周 | -0.83% | 478/2029 |
| 近一月 | -3.17% | 827/2018 |
| 近一季 | -8.06% | 1160/1966 |
| 近半年 | -1.04% | 622/1877 |
| 近一年 | 14.56% | 302/1753 |
| 近两年 | 89.06% | 308/1324 |
| 近三年 | 54.10% | 217/1010 |
| 成立以来 | 71.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.41% 945/4961 |
21.94% 1148/5312 |
- - |
- - |
| 2025 | 37.49% 896/4813 |
4.03% 1003/3635 |
2.54% 1505/4076 |
26.72% 1335/4524 |
1.72% 1252/4813 |
| 2024 | 10.43% 1410/3463 |
-1.97% 1303/2808 |
-0.37% 751/3014 |
12.76% 2295/3129 |
0.27% 1241/3463 |
| 2023 | -9.45% 1165/2656 |
7.06% 608/2280 |
-4.47% 1184/2385 |
-6.10% 1432/2515 |
-5.71% 1472/2655 |
| 2022 | -20.14% 937/2207 |
-13.35% 743/1919 |
4.94% 957/2016 |
-11.18% 501/2113 |
-1.12% 1680/2208 |
| 2021 | 17.63% 226/1822 |
-0.03% 324/1255 |
14.50% 253/1330 |
5.21% 287/1466 |
-2.32% 1409/1822 |
| 2020 | 46.73% 205/1250 |
0.39% 163/1028 |
18.82% 322/1067 |
14.62% 270/1164 |
7.32% 719/1184 |
| 2019 | 30.18% 487/1092 |
28.50% 306/739 |
-8.25% 586/788 |
3.34% 259/850 |
6.85% 536/918 |
| 2018 | -20.65% 196/834 |
- - |
-11.41% 363/631 |
-7.94% 473/660 |
-10.75% 220/682 |
| 2017 | 2.66% 438/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.39% 417/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证500指数增强C VS. 长安沪深300非周期A(740101) |